those observed for analogous reaction of ketones.1c,e,2-4 This
is likely a result of the different rates and selectivities of
reduction of the anti and syn isomers.1c,2 However, five- or
six-membered cyclic imines, which lack this stereochemical
issue, undergo ATH induced by catalysts 1-3 with excellent
enantioselectivities.1f,3,5,6 In addition, ATH of acyclic imines
possessing sterically bulky N-substituents, such as N-
(diphenylphosphinoyl) that causes a predominance of the anti
geometry, leads to the corresponding N-(diphenylphosphi-
noyl)amines with high degrees of enantioselectivity.7
steps.10,11 Catalytic asymmetric intramolecular amidation of
prochiral sulfamate esters using chiral Ru(II)-pybox and
valerolactam-derived Rh(II) catalysts has also been employed
to generate chiral cyclic sulfamidates with high enantiose-
lectivities.12 Recently, an efficient enantioselective synthesis
of cyclic sulfamidates (5) employing chiral Pd-catalyzed
asymmetric hydrogenation of corresponding cyclic imines
(4) has been reported.10 Although this method provides cyclic
sulfamidates 5 in high yields and ee’s, it requires the use of
high (600 psi) H2 pressures, only trifluoroethanol as the
solvent, and 2.4 mol % of the expensive chiral (S,S)-f-
binaphane ligand, of which only the (S,S) isomer is com-
mercially available.
Scheme 1
In investigations aimed at the development of new methods
for the preparation of functionalized chiral amines, we have
uncovered a highly efficient and practical ATH-based
procedure for the synthesis of chiral cyclic sulfamidates (5)
starting with the corresponding cyclic imines (4). This
methodology uses a 5:2 mixture of HCO2H and Et3N as the
hydrogen source along with the chiral Rh catalysts (S,S)- or
(R,R)-2, Cp*RhCl(TsDPEN) (Cp* ) pentamethylcyclopen-
tadienyl and TsDPEN ) (1S,2S)- or (1R,2R)-N-p-toluene-
sulfonyl-1,2-diphenylethylenediamine). The cyclic imines
employed in these processes are conveniently prepared from
hydroxyl ketones (6) and sulfamoyl chloride by using
previously described procedures.10
The cyclic imine 4a, (R,R)-2 catalyst (0.5 mol %, S/C )
200), and 5:2 mixture of HCO2H/Et3N (azeotropic mixture)13
in various solvents (EtOAc, CH2Cl2, THF, DMF, MeOH,
toluene, CH3CN) were employed in an effort aimed at
optimizing the ATH reaction conditions. The results (see
Supporting Information) show that in each case 4a is
completely converted to the cyclic sulfamidate (5a) with high
enantioselectivity within 1 h at room temperature. In addition,
ATH of 4a in ethyl acetate takes place completely in 0.5 h
even using 0.1 mol % of catalyst (R,R)-2 (S/C ) 1000), while
the reaction with 0.1 mol % of (R,R)-2 in dichloromethane
solvent requires 3.5 h. Therefore, ethyl acetate was selected
as the solvent for all of the ATH reactions of imines 4.
The preformed chiral Rh(III) complex (R,R)-25 with a 5:2
mixture of HCO2H and Et3N as the hydrogen source was
found to be the best condition for performing the ATH
reactions of the imines 4. The ATH of 4a (0.1 M in ethyl
On the basis of the factors described above, we envisioned
that the cyclic sulfamate imines 4, which are activated by
the electron-withdrawing sulfamidate group and are free of
syn- and anti-isomerism, would be good substrates for highly
enantioselective ATH reactions. Moreover, cyclic sulfami-
dates (5), possessing both a chiral carbon that bears an amine
moiety and a reactive cyclic sulfamidate group, are valuable
precursors in the syntheses of various chiral 1,2-functional-
ized amine derivatives including 1,2-amino alcohols, R-ami-
no acids, and nitrogen-containing heterocycles (Scheme 2).8,9
Typically, cyclic sulfamidates are prepared from chiral amino
alcohols and diols through routes that involve several
(2) Nugent, T. C.; El-Shazly, M. AdV. Synth. Catal. 2010, 352, 753.
(3) Haraguchi, N.; Tsuru, K.; Arakawa, Y.; Itsuno, S. Org. Biomol.
Chem. 2009, 7, 69.
Scheme 2
. 1,2-Functionalized Chiral Amines through ATH of
(4) Uematsu, N.; Fujii, A.; Hashiguchi, S.; Ikariya, T.; Noyori, R. J. Am.
Chem. Soc. 1996, 118, 4916.
Cyclic Imines 4 to Form Cyclic Sulfamidate 5
(5) Mao, J.; Baker, D. C. Org. Lett. 1999, 1, 841.
(6) Blackmond, D. G.; Ropic, M.; Stefinovic, M. Org. Process Res. DeV.
2006, 10, 457.
(7) Kwak, S. H.; Lee, S. A.; Lee, K.-I. Tetrahedron: Asymmetry 2010,
21, 800.
(8) Roszkowski, P.; Wojtasiewicz, K.; Leniewski, A.; Maurin, J. K.;
Lis, T.; Czarnocki, Z. J. Mol. Catal. A: Chem. 2005, 232, 143.
(9) Bower, J. F.; Rujirawanich, J.; Gallagher, T. Org. Biomol. Chem.
2010, 8, 1505.
(10) Wang, Y.-Q.; Yu, C.-B.; Wang, D.-W.; Wang, X.-B.; Zhou, Y.-G.
Org. Lett. 2008, 10, 2071.
(11) Melendez, R. E.; Lubell, W. D. Tetrahedron 2003, 59, 2581.
(12) (a) Zalatan, D. N.; Du Bois, J. J. Am. Chem. Soc. 2008, 130, 9220.
(b) Milczek, E.; Boudet, N.; Blakey, S. Angew. Chem., Int. Ed. Engl. 2008,
47, 6825.
(13) Narita, K.; Sekiya, M. Chem. Pharm. Bull. 1977, 25, 135.
Org. Lett., Vol. 12, No. 18, 2010
4185